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Skin dendritic cells of patients with atopic dermatitis 
(AD) are well characterized, but less is known about 
their peripheral blood precursors. The aim of this study 
was to investigate the phenotypic features and chemo-
kine production of myeloid pre-dendritic cells of patients 
with AD ex vivo and after stimulation with Staphylococ-
cus enterotoxin B and thymic stromal lymphopoietin, 
representing an AD-like microenvironment. The expres-
sion of cell surface markers was measured by flow cyto-
metry, while chemokine production was monitored with 
chemokine antibody array and confirmed by enzyme-
linked immunoassays. AD pre-dendritic cells expressed 
higher levels of FcεRI and the maturation and surface 
activation markers tended to be altered. They produ-
ced both AD (CCL17/18/22) and maturation-related 
(CCL3/4/5) chemokines at higher level than controls. 
The production of CCL3/4 and CCL18 were significant-
ly higher even without AD-specific stimulation, while 
CCL17 and CCL22 only after stimulation. These re-
sults indicate that circulating AD pre-dendritic cells are 
premature and bear atopic characteristics even without 
tissue-specific stimulation, suggesting that their develop-
ment is not only influenced by the skin microenviron-
ment, but even earlier by the local milieu in the blood. 
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Atopic dermatitis (AD) is a common inflammatory skin 
disease, in which both T cells and dendritic cells (DC) 
play crucial roles in the development of skin inflamma-
tion. AD is characterized by Th2- and Th22-type T-cell 
infiltration in both the initial and chronic phases (1–6). 
Beside T cells, DCs also represent the main partici-
pants in the pathogenesis of AD, since they contribute 
to inflammation both through their T-cell-polarizing ca-
pacity, and through direct cytokine and chemokine pro-
duction. DCs serve as sentinels of the immune system 
and represent a heterogeneous family of myeloid cells. 
Skin myeloid DCs can be classified according to their 
tissue location and their surface molecule expression: 
Langerhans’ cells ((LCs) CD207+(Langerin+), CD1a+, 
FcεRI+)) are the main cell types of the epidermis (7), 
whereas dermal myeloid DCs (CD11c+, CD1c+, FcεRI +) 
can be found throughout the entire dermal compartment. 
Under inflammatory conditions, such as in AD skin, yet 
another cell type, the inflammatory dendritic epidermal 
cells ((IDECs) CD1a+, CD206+)) develops (8, 9). 
In addition to monocytes, blood DCs are thought to be 
the precursors of DCs located in the skin and other tissues 
(10, 11), and are often described as precursor DCs (pre-
DCs). The precursor-progeny connection between CD1c+ 
blood DCs and tissue CD1c+ DCs is also supported by in 
vitro differentiation and gene expression analysis (12). 
In AD, it has emerged that peripheral blood pre-DCs can 
serve as precursors, not just of dermal DCs, but also of 
skin inflammatory DCs (11, 13).
In addition to their T-cell-polarizing cytokine produc-
tion DCs are also important sources of chemokines. 
Several research groups have observed that in patients 
with AD skin, DCs produce mainly CCL17, CCL18 and 
CCL22 (3, 14). CCL17 and CCL18 are considered as 
AD-related chemokines produced by skin myeloid DCs, 
which play a role in the trafficking of memory T cells 
and in regulating the Th2 immune response. CCL22, 
which is an AD-related chemokine, is considered to be 
released mainly by plasmocytoid DCs (3). On the other 
hand, little information on the chemokine production 
of blood DCs in AD is available.
Since the peripheral blood pre-DCs are poorly charac-
terized in AD, we aimed to examine their characteristic 
features. In our previous study, AD pre-DCs showed 
differences in the production of T-cell-polarizing cy-
tokines compared with pre-DCs from healthy controls 
(15). The present study continues the detailed pheno-
typic characterization of these cells, focusing on their 
activation and maturation stage and their chemokine 
production, in order to determine whether they differ 
from myeloid pre-DCs of healthy individuals ex vivo 
and after stimulation with Staphylococcus enterotoxin 
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B (SEB) and thymic stromal lymphopoietin (TSLP), 
which represent an AD-like microenvironment. Our 
results indicate that peripheral blood pre-DCs derived 
from patients with AD are more mature than control 
pre-DCs and that they are able to produce chemokines 
that are either AD specific or represent their early ma-
turation stage even without stimulation, although this 
chemokine profile became more intense and disease-
specific after tissue-specific stimulation.
METHODS
Patients and controls
Peripheral blood was obtained from patients with chronic 
AD (n = 12, 8 males, 4 females, age: 25.5 ± 7.5 years, Table I) 
and buffy coat (n = 10) was used as the healthy controls. All 
patients fulfilled the diagnostic criteria established by Hanifin 
& Rajka (16). Patients who took part in this study had severe 
skin symptoms and had not been treated with oral glucocorti-
costeroids or other systemic immunomodulatory agents for at 
least 4 weeks, or with antihistamines or topical corticosteroids 
for at least 5 days, prior to blood sampling. Disease activities 
(mean ± SD) were determined by the severity Scoring of Atopic 
Dermatitis (SCORAD) index: 49.3 ± 11.1) and total serum IgE 
levels (2,598 ± 1,402 kU/l) were also determined. In all patients, 
hyper IgE syndrome (HIES) was excluded according to the HIES 
clinical scoring system (17). Informed consent was obtained 
from all participants according to the principles of the Declara-
tion of Helsinki. The local ethics committee of the University 
of Debrecen, Hungary, approved the study.
Cell isolation and culture 
Peripheral blood mononuclear cells (PBMCs) were obtained by 
Ficoll-Paque Plus (GE Healthcare Bio-Science AB, Uppsala, 
Sweden) gradient centrifugation from the peripheral blood both 
of patients with AD and of healthy controls. CD1c+ myeloid 
DCs were isolated from PBMCs using the CD1c+ (BDCA1+) 
Dendritic Cell Isolation Kit (Miltenyi Biotech GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer’s instruc-
tions. Purified DCs were cultured in RPMI 1640 (Miltenyi 
Biotech GmbH) medium supplemented with antibiotics (PAA 
Laboratories GmbH, Pasching, Austria) and 10% foetal bovine 
serum (FBS) (Lonza Group Ltd, Basel, Switzerland) for 48 h, 
in the presence (stimulated) or absence (unstimulated) of 30 
ng/ml TSLP (eBioscience Inc., San Diego, CA, USA) and 100 
ng/ml staphylococcal enterotoxin B (SEB) (Sigma Aldrich Co., 
St Louis, MO, USA). DCs (5–6 × 105) were cultured in 200 μl 
cell culture medium in 1 or 2 wells of a 96-well flat-bottomed 
plate and supernatants were collected for chemokine exami-
nations. Due to the relatively small number of cells available, 
fluorescence-activated cell sorting (FACS) analysis has not 
been performed with freshly isolated cells, but we performed 
preliminary experiments to exclude the possibility that cell 
culture could significantly modify the results of the cell surface 
marker examinations. 
Phenotypic characterization of DCs by 4-colour staining of cell 
surface markers
After incubation, the cells were harvested, washed in phospha-
te-buffered saline (PBS) with 5% FBS and 0.5 mM EDTA, 
and resuspended in FACS buffer (PBS containing 1% bovine 
serum albumin) and aliquoted into 4 wells of a 96-well plate (1 
for the negative control, 1 isotype control, and 2 for staining). 
Cells were stained with the following dye-tagged cell-surface 
marker antibodies: APC-Cy7 anti-human CD1c and PerCP-
Cy5.5 anti-human CD11c to identify CD1c+/CD11c+ cells, 
APC anti-human CD1a and APC anti-human CD207 to exclude 
LCs, and PE anti-human FcεRI, APC-Cy7 anti-human CD206, 
PerCP-Cy5.5 anti-human CD83 and PE anti-human CD86 to 
examine their characteristics, maturation and activation state. 
PE mouse IgG2b, κ isotype control, APC mouse IgG1, κ 
isotype control, PerCP/Cy5.5 mouse IgG1, κ isotype control, 
APC/Cy7 mouse IgG1, and κ isotype control were used as 
isotype controls. All the antibodies were from Biolegend, San 
Diego, CA, USA. Cells were stained for 30 min in the dark at 
4°C. Stained cells were washed with FACS buffer and fixed 
by intracellular (IC) fixation buffer (eBioscience, San Diego, 
CA, USA) for 20 min in the dark at room temperature. After 
fixation, cells were washed and kept in FACS buffer at 4°C 
until measurement. The expression of cell surface markers was 
measured by flow cytometry.
Flow cytometry
Flow cytometric measurements were carried out on fixed cells 
in 96-well plates on a BD FACS Array instrument (Becton 
Dickinson, San Jose, CA, USA). Forward (FSC) and side-
light scattering (SSC) was used to detect cellular objects and 
to exclude debris and clustered cells. PE-stained fluorescence 
was excited by a 532-nm laser and detected by a 585/42-nm 
band-pass filter; APC-stained samples were excited by a 635-
nm laser and measured using a 660/20-nm filter; PerCP-Cy5.5-
stained samples were excited by a 532-nm laser and measured 
using a 695/40-nm filter; and APC-Cy7-stained samples were 
excited by a 635-nm laser and measured using a 780/60-nm 
filter. Flow cytometric acquisition of 1 sample typically inclu-
ded 100,000–500,000 cells. Data was exported and evaluated 
using FCS Express 4 Flow Cytometry (De Novo Software, Los 
Angeles, CA, USA).
Identification of the secreted chemokines by chemokine array
Chemokine production was measured using the Proteome 
Profiler Human Chemokine Array Kit (R&D Systems Abing-
don, UK) from the cell culture supernatant of the previously 
isolated unstimulated cells (5 atopic and 5 control samples, 
marked in Table I). The assay was carried out according to the 
manufacturer’s instructions. 
Table I. Characteristics of patients with chronic atopic dermatitis
Pat. No. Age, years Sex
SCORAD 
score
Increased 
IgE level
1** 40 Male 55 Yes
2 37 Male 72 Yes
3* 25 Female 41 Yes
4* 22 Male 39 Yes
5** 25 Female 42 Yes
6 10 Male 38 Yes
7** 25 Female 41 NA
8* 23 Male 52 Yes
9* 23 Male 59 Yes
10* 25 Female 51 Yes
11** 23 Male 39 Yes
12** 28 Male 63 Yes
*Dendritic cell supernatants of the patients were used in Proteome Profiler 
Array. **Dendritic cell supernatants of the patients were used in ELISArray, 
and in conventional enzyme-linked immunoassay (ELISA) experiments.
Serum IgE reference range: 0–100 kU/l.
NA: not available; SCORAD: Scoring Atopic Dermatitis.
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Validation of chemokine production by ELISAs 
To validate our results, the production of CCL3, CCL4, CCL5, 
CXCL10, CCL17 and CCL22 chemokines were detected si-
multaneously from DC supernatants of 5 atopic and 5 control 
samples using the Human Common Chemokines Multi-Analyte 
ELISArray kit (Qiagen, Hilden, Germany). Since this ELI-
SArray kit is a qualitative rather than a precise, quantitative 
assay, the exact amount of AD-related CCL17,CCL18 and 
CCL22 chemokines were also analysed using the CCL17/
TARC, CCL18/PARC and CCL22/MDC Quantikine ELISA 
Kits (R&D Systems, Minneapolis, MN, USA), both according 
to the manufacturer’s instructions. In the case of the latter, 
conventional ELISAs the supernatants of both unstimulated 
and stimulated cells were investigated. The detection limits in 
Quantikine ELISAs are: CCL17: 7 pg/ml, CCL18: 1.7 pg/ml, 
and CCL22: 62.5 pg/ml.
Statistical analysis
SPSS ver. 18.0 software (SPSS Inc., Chicago, IL, USA) was 
used for statistical analysis. To assess the distribution of the 
data, the Kolmogorov–Smirnov test was used. Because of their 
normal distribution, we determined mean with corresponding 
95% confidence interval or mean ± standard deviation (SD) va-
lues and used the independent t-test for statistical comparison of 
the experimental data. To analyse the homogeneity of variance 
of these data, F test was used. Differences were considered to 
be significant when p < 0.05.
RESULTS
Blood pre-dendritic cells from patients with atopic 
dermatitis express significantly more FcεRI and show 
tendentially altered presence of maturation markers 
To examine the phenotypic features of the separated 
CD1c+ pre-DCs, and to exclude the non-relevant FACS-
detected events, CD1c+/CD11c+ pre-DCs were gated, 
and thus more than 90% of the gated cells were positive 
for both the CD1c and the CD11c markers. The gated 
cells were negative for CD207 (Langerin-LC marker) 
and did not express CD1a (Fig. 1A).
When examining the presence of the FcεRI, signifi-
cantly higher expression of this receptor could be detec-
ted on the surface of AD pre-DCs compared with their 
healthy counterparts (58.7% vs. 29.8%, respectively, 
p = 0.004; Table II, Fig. S1B1) and the difference was 
Fig. 1. Identification of the chemokines produced by atopic dermatitis (AD) 
pre-dendritic cells (DCs) in comparison with the chemokine production of 
healthy pre-DCs. The supernatants of the isolated blood DCs were collected 
and the relative levels of chemokines were determined by a Proteome Profiler 
Array according to the manufacturer’s instructions. The relative levels of 
the AD- and control-related chemokines were determined by calculating 
the mean pixel densities of the individual blots normalized to the sample 
control. (A) Localization of the chemokine probes in the membranes. (B) 
Representative dot blots showing the relative expression of chemokines 
produced by control and atopic pre-DCs.
Table II. Expression of cell surface markers on atopic dermatitis (AD) and control pre-dendritic cells (DC) ex vivo and after tissue-
specific stimulation
Cell surface 
markers
AD pre-DCs 
(unstimulated)
Healthy pre-DCs 
(unstimulated) p-value
AD pre-DCs 
(stimulated)
Healthy pre-DCs 
(stimulated) p-value
CD1c+ (%) ˃ 90 ˃ 90 – ˃ 90 ˃ 90 –
CD11c+ (%) ˃ 90 ˃ 90 – ˃ 90 ˃ 90 –
CD1a+ (%) ˂ 10 ˂ 10 – ˂ 10 ˂ 10 –
CD207+ (%) ˂ 10 ˂ 10 – ˂ 10 ˂ 10 –
FcεRI+ (%) 58.70 [46.22; 71.18] 29.76 [20.59; 38.93] p = 0.004 60.21 [45.24; 75.19] 29.95 [8.80; 51.10] p = 0.044
CD206+ (%) 48.61 [37.42; 59.80] 64.76 [50.45; 79.06] Not significant 38.48 [25.55; 51.40] 54.42 [44.27; 64.57] Not significant
CD86+ (%) 83.44 [75.83; 91.05] 74.53 [67.10; 81.95] Not significant 90.64 [85.54; 95.74] 84.05 [74.25; 93.85] Not significant
CD83+ (%) 63.04 [54.72; 71.36] 57.95 [48.21; 71.69] Not significant 68.67 [53.24; 84.09] 50.15 [30.46; 69.84] Not significant
CD1c+ and CD11c+ cells separated from the blood of patients with atopic dermatitis (AD) expressed significantly more FcεRI than the cells derived from 
healthy individuals. The CD206 mannose receptor, which is thought to be expressed on less mature cells, were tended to occur less frequently, while 
CD83 and CD86 (maturation and activation markers) were tended to be expressed more frequently in AD patient-derived cells than in control cells, 
although these differences were not significant. The differences could not reach the significancy level, even after stimulation, but the tendency can also be 
observed.
Percentages of cells expressing cell surface markers are described using mean with corresponding 95% confidence interval.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2540
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also significant in the case of stimulated cells (60.2% 
vs. 29.95%, respectively, p = 0.04, Table II). Detec-
tion of surface markers reflecting the activation and 
maturation state of the cells showed that the presence 
of these molecules tends to alter on DCs derived from 
patients with AD. The CD206 mannose receptor, which 
is known to be expressed on less mature cells, appeared 
on the surface of AD pre-DCs less frequently than on 
the surface of healthy pre-DCs (unstimulated: 48.6% 
vs. 64.8%, p = 0.536, stimulated: 38.47% vs. 54.42%, 
p = 0.116). The CD83 and CD86 markers exhibited an 
opposite expression pattern as they were expressed 
more frequently on AD patient-derived cells than on 
control cells (unstimulated: 63.0% vs. 57.9%, p = 0.96 
and 83.4% vs. 74.5%, p = 0.12, respectively, Table II, 
Fig. S1B1, stimulated: 68.66% vs. 50.15%, p = 0.18 
and 90.63% vs. 84.5%, p = 0.22, respectively, Table 
II). Although none of the 3 examined surface markers 
showed significantly altered expression on AD DCs, 
their consistent and unidirectional changes suggest that 
most of the AD DCs are in a premature state. 
Blood pre-dendritic cells from patients with atopic 
dermatitis are able to produce both atopic dermatitis-
specific and maturation-related chemokines – screening 
of chemokine production by Proteome Profiler Array
The chemokine production potential of the AD DCs 
was examined with a screening method that can simul-
taneously detect the release of 31 different human che-
mokines. When investigating chemokine production 
using the Proteome Profiler Chemokine Array, the data 
revealed that chemokines released from AD pre-DCs 
could be separated into 2 groups (Figs 1 and 2). The 
first group included those chemokines that were detec-
ted in the supernatant of both the patient and the control 
pre-DCs in a similar amount: CXCL4, CXCL7, CXCL8 
and CXCL16 (Fig. 2A). The second group included 
those chemokines that were produced at a significantly 
higher amount or solely by the AD pre-DCs: CCL3/4, 
CCL5, CCL17, CCL18, CCL19, CCL20, CCL22, 
CXCL1, CXCL5 and CXCL10 (p < 0.05 in the case 
of CCL3/4, CCL17, CCL22, CXCL1 and CXCL10; 
while in the case of CCL5, CCL18, CCL19, CCL20 
and CXCL5 p > 0.05, not significant; Fig. 2B). From 
this group, CCL17, CCL18 and CCL22 are known as 
AD-related chemokines (Box 1, Fig. 2B), while CCL3, 
CCL4, CCL5 and CXCL10 can be defined as chemo-
kines of maturing DCs (Box 2, Fig. 2B).
Re-evaluation of increased chemokine production by 2 
different ELISAs
The production of the most important chemokines 
from the second group (the chemokines of maturing 
DCs such as CCL3, CCL4, CCL5, CXCL10 and the 
AD-related CCL17, CCL22) was also investigated by 
a Multi-Analyte ELISArray from the supernatant of 
unstimulated cells. CCL3 and CCL4 could be detected 
in a significantly higher amount in the samples of AD 
pre-DCs compared with controls (Fig. 3A), similar 
to that observed during our investigations using the 
Proteome Profiler Chemokine Array (CCL3 meanod450: 
1.77 ± 0.36 vs. 0.15 ± 0.01, respectively, p = 0.0098 
and CCL4 meanod450: 1.28 ± 0.41 vs. 0.26 ± 0.11, re-
spectively, p = 0.0498). Regarding CCL17, CCL22 
and CCL5, we could not detect significant differences 
between the 2 groups (CCL17 meanOD450: 0.25 ± 0.14 
and 0.124 ± 0.10 in atopic vs. control samples; p = 0.47; 
CCL22 meanOD450: 2.37 ± 0.1 and 1.74 ± 1.2 in atopic 
vs. control samples; p = 0.48; CCL5 meanOD450: 
0.225 ± 0.3788 and 0.0342 ± 0.04 in atopic vs. control 
samples, p = 0.458; Fig. 3A), which may be due either 
to the different sensitivity levels of the 2 methods or to 
the high SD of the samples. In AD samples CXCL10 
could be detected at a low level, but it could not be 
detected in the supernatant of control cells at all (data 
not shown).
In the case of the 2 AD-related cytokines (CCL17 
and CCL22) together with CCL18, more precise and 
Fig. 2. Results obtained by the Proteome Profiler Chemokine Antibody 
Array. (A) Chemokines produced by both atopic dermatitis (AD) and 
control pre-dendritic cells (DCs) at similar levels. Columns represent the 
mean±standard deviation (SD) of 5 patients and 5 controls. *p ˂  0.05. (B) 
Chemokines produced mainly or exclusively by AD pre-DCs. Columns 
show the mean ± SD of 5 patients and 5 controls. Chemokines in Box 1 are 
AD-related chemokines, while Box 2 represents the chemokines that are 
produced by DCs at an early maturation stage (according to the literature). 
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reliable conventional ELISA investigations were also 
carried out, investigating both unstimulated and stimu-
lated pre-DC supernatants. With conventional ELISA 
we could detect that unstimulated AD DCs are able to 
produce both CCL17 and CCL22 in higher amounts 
than the control cells, but the differences between the 2 
groups became statistically significant after AD-specific 
stimulation (Fig. 3B and C.). CCL18 could be detected 
in a significantly higher amount in the supernatant of 
atopic DCs, both with and without any further stimu-
lation (mean: 810 pg/ml vs. 84.1 pg/ml, respectively, 
p = 0.006 when examining unstimulated, or mean: 915.5 
pg/ml vs. 280.14 pg/ml, respectively, p = 0.01 in the case 
of stimulated cells) (Fig. 3D).
DISCUSSION
This study focused on the phenotypic characteristics 
and chemokine production of the poorly investigated 
CD1c+ blood pre-DCs of patients with AD. These cells 
are thought to be the precursors of skin dermal DCs 
(11, 12), and they may also serve as the precursors 
of skin inflammatory DCs (11). Investigating blood 
pre-DCs can give information on when or where skin 
mDCs acquire their AD-specific characteristics, i.e. 
exclusively in the skin microenvironment or even in the 
blood if they are already influenced by some disease-
specific factors. These questions can be answered only 
by examining DCs directly separated from peripheral 
blood, instead of applying DCs that have been diffe-
rentiated in vitro from monocytes, and although this 
method results in fewer cells from the same amount 
of blood, their characteristics more closely resemble 
the physiological conditions.
The expression of FcεRI on DCs in AD skin was 
studied almost 20 years ago (18, 19). Their surface ex-
pression shows high levels both on LCs and IDECs and 
they are suggested to regulate inflammatory processes 
(20). Our own results showed a significantly elevated 
level of these receptors on blood pre-DCs, confirming 
previous literature data (21, 22). The higher numbers of 
this receptor on the surface of blood CD1c+ precursor 
cells may be the result of elevated serum IgE levels in 
patients with AD. Blood DCs can use this receptor for 
IgE-mediated allergen presentation (22); moreover, 
the presence of specific IgE and the receptor on their 
surface increases the efficiency of antigen uptake and 
presentation after arriving to the skin (20, 23).
Based on the expression of the CD206 marker 
(mannose receptor), immature and mature DCs can 
be distinguished, since most of the mature DCs do not 
express this protein on their surface in high amounts 
(24–26). We detected this marker in both the diseased 
and the control groups, but fewer AD pre-DCs tended 
to express them, suggesting a premature state of DCs 
in AD. With respect to the expression of the CD83 and 
CD86 maturation and activation markers on the surface 
of blood DCs, the literature is controversial (21, 23). 
Our results suggest higher expression of these markers 
on the pre-DCs of patients with AD, and although 
neither CD206 nor CD83/CD86 showed significantly 
altered expression (even after stimulation) on DCs from 
patients with AD, their consistent and unidirectional 
change may suggest that AD pre-DCs are in a premature 
state. The lack of significance in our present results and 
the inconsistency in the data in the literature related to 
these maturation markers can be explained by a recent 
observation that it is likely that not the entire blood 
CD1c+ population, but rather a subpopulation, is in a 
premature state (15). In that study a greater population 
of more active and larger DCs with decondensed nuclei 
and with low DAPI intensity was identified in the blood 
of patients with AD, and the AD characteristic cytokine 
production was also assigned to these cells (15). 
The current study also investigated the chemokine 
production of AD pre-DCs, since DCs are important 
sources of chemokines, and there is insufficient infor-
mation on the chemokine production of these cells in 
the blood of patients with AD. First we applied a Pro-
teome Profile Chemokine Array to screen the most im-
Fig. 3. Validation of the production of the atopic dermatitis (AD)-specific and maturation-related chemokines by enzyme-linked immunoassay (ELISA). (A) 
From the supernatants of 5 AD and 5 control pre-dendritic cell (DC) samples the most important chemokines (chemokines representing early maturation 
stage: CCL3, CCL4, CCL5; AD-related chemokines: CCL17, CCL22) were also investigated by ELISArray. AD pre-DCs produced CCL3 and CCL4 in 
significantly higher amounts than the control cells, similar to that observed during our investigations using the Proteome Profiler Chemokine Array, but 
regarding CCL5, CCL17 and CCL22 significant differences could not be detected with this method. (B–D) Examination of AD-related chemokines by 
conventional ELISA. AD pre-DCs are able to produce CCL17 and CCL22 in a significantly higher amount than control DC after tissue-specific stimulation 
(thymic stromal lymphopoietin (TSLP) + Staphylococcus enterotoxin B (SEB)). In addition, they have the potential to produce CCL18 with or even 
without any stimulation. Columns represent the mean ± standard deviation (SD) of 5 patients and 5 controls. *p ˂  0.05. **p ˂  0.01.
[AQ2]
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portant chemokines produced by AD pre-DCs ex vivo, 
then we tried to confirm our results by an ELISArray. 
Furthermore, we were also interested in the stimula-
tory effect of the tissue-specific microenvironment, 
so we compared the chemokine-producing capacity of 
unstimulated cells (representing blood pre-DCs) and 
DCs after stimulation with TSLP and SEB using more 
precise conventional sandwich ELISA.
According to our results from the Proteome Profiler 
Array the chemokines were divided into 2 groups: (i) 
chemokines that were produced by AD and control pre-
DCs in a similar amount; (ii) chemokines produced in a 
higher amount by AD pre-DCs. In the first group, both 
AD and healthy pre-DCs produced CXCL4, CXCL7, 
CXCL8 and CXCL16 in similarly high amounts sug-
gesting that their production is characteristic of blood 
pre-DCs, but independent of the presence of AD. 
The members of the second group (CCL3, CCL4, 
CCL5, CCL17, CCL18 and CCL22, except for 
CXCL10) were found to be released in higher amounts 
by blood pre-DCs of patients with AD (detected both 
by Proteome Profiler Array and ELISAs). Among 
them CCL17, CCL18 and CCL22 are considered to be 
AD-related chemokines that are also produced by skin 
DCs of patients with AD, and have an important role 
in regulating the Th2 immune response and also play 
a role in the trafficking of memory T cells (3, 23, 26). 
Gene expression of the inflammation-related CXCL10, 
CCL3, CCL4 and CCL5 were detected not only in the 
skin of patients with AD, but also in the skin of patients 
with other inflammatory skin diseases (14), indicating 
that the elevated level of these chemokines is a general 
characteristic of chronic inflammation, rather than an 
AD-specific factor.
The chemokine production pattern of blood DCs in 
patients with AD described above can also give some 
information on their maturation, since DCs at different 
maturation stages produce different combinations of 
chemokines (27–30). Premature DCs that show early 
signs of maturation start to produce CCL2, CCL3, 
CCL4, CCL5, CXCL8 and CXCL10 in high amounts 
(27–30). In our study the production of CCL3, CCL4, 
CCL5 and CXCL10 inflammatory chemokines mainly 
by AD pre-DCs, further confirmed their premature 
status. 
Taken together, the characterization of cell surface 
markers and the chemokine production of blood pre-
DCs in patients with AD indicate that these cells are in 
a premature stage, and are able to produce AD-specific 
chemokines even in the peripheral blood. Considering 
this AD-specific chemokine production and our earlier 
finding on their capacity to release AD-specific cyto-
kines, we suggest that development of AD DCs are 
markedly influenced by the microenvironment in the 
blood and not just by the skin milieu. However, their 
chemokine and cytokine profile becomes more intense 
and disease-specific after tissue-specific stimulation. 
The bloodstream of patients with AD contains unique 
sets of cytokines, such as IL-4, IL10, IL-13, CCL17 
(TARC) and TSLP (31–38), which can allow these cells 
to reach the early stage of maturation. Novel biological 
therapies (e.g. Dupilimab or anti-TSLP monoclonal 
antibodies) used against these molecules can have a 
doubly beneficial impact by modifying the effect of 
these cytokines both in the skin and in the blood of 
patients with AD, thus influencing the maturation and 
the function of the precursor DCs in the blood (39, 40). 
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